Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QuoNova, which is 88.7% owned by XL TechGroup, has generated preliminary in-vitro data that indicates high efficacy of selected Quorum Sensing Blockers in inhibiting biofilm formation by methicillin-resistant Staphylococcus aureus strains and fungal organisms such as Candida species.
Subscribe to our email newsletter
Importantly, QuoNova’s QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of infection from such drug-resistant bacteria, without inducing resistance itself. QuoNova recently demonstrated the efficacy of its QSB technology in a predictive animal model where QSBs significantly reduced the ability of clinically relevant bacteria to colonize secondary burn wounds. In addition, a marked synergy with Silver Sulfadiazine (SSD), a commonly used antibacterial preparation, was observed.
Heiri Gugger, CEO of QuoNova, said: “These are promising results which significantly broaden the reach of our platform and further illustrate the impact of QuoNova’s QSB technology in combating the detrimental effects of biofilms.”